Metabolomic Characterization of Acute Ischemic Stroke Facilitates Metabolomic Biomarker Discovery

Acute ischemic stroke (AIS) is characterized by a sudden blockage of one of the main arteries supplying blood to the brain, leading to insufficient oxygen and nutrients for brain cells to function properly. Unfortunately, metabolic alterations in the biofluids with AIS are still not well understood. In this study, we performed high-throughput target metabolic analysis on 44 serum samples, including 22 from AIS patients and 22 from healthy controls. Multiple-reaction monitoring analysis of 180 common metabolites revealed a total of 29 metabolites that changed significantly (VIP > 1, p < 0.05). Multivariate statistical analysis unraveled a striking separation between AIS patients and healthy controls. Comparing the AIS group with the control group, the contents of argininosuccinic acid, betaD-glucosamine, glycerophosphocholine, L-abrine, and L-pipecolic acid were remarkably downregulated in AIS patients. Twenty-nine out of 112 detected metabolites enriched in disturbed metabolic pathways, including aminoacyl-tRNA biosynthesis, glycerophospholipid metabolism, lysine degradation, phenylalanine, tyrosine, and tryptophan biosynthesis metabolic pathways. Collectively, these results will provide a sensitive, feasible diagnostic prospect for AIS patients.

Automated summary

Acute ischemic stroke is a condition where one of the brain's main arteries is suddenly blocked, leading to insufficient oxygen and nutrients for brain cells. In this study, the metabolic changes in the biofluids of AIS patients were analyzed, revealing 29 significantly altered metabolites. The results showed a clear distinction between AIS patients and healthy controls, providing a sensitive and feasible diagnostic prospect for AIS patients.